Javascript must be enabled to continue!
Clinicopathological Factors Predicting Long‐term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma
View through CrossRef
AbstractPeripheral cholangiocarcinoma (PCC) is clinically challenging because patients typically do not present until the disease is relatively advanced. Three‐year to 5‐year survival rates even with resection thus remain dismal. This study aimed to determine the clinicopathological factors for predicting overall survival longer than 5 years in PCC patients treated with hepatectomy. From 1977 to 1997, the clinicopatholgical features of 11 PCC patients who underwent hepatectomy with long‐term overall survival (group A) were reviewed. Comparison was made with the clinical features and factors influencing the outcome of 70 PCC patients who survived less than 5 years after hepatectomy (group B). Of 81 PCC patients undergoing hepatectomy, 11 (13.6%) were 5‐year survivors. The 81 PCC patients comprised 32 men and 49 women, with a mean age of 56.0 years (range: 34–83 years). Univariate analysis showed that female gender, absence of physical findings, a higher percentage of presence of mucobilia, early staged tumor, intraductal papillary tumor growth, and curative hepatic resection were more frequent in group A patients than group B patients. However, multivariate logistic regression analysis showed that absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatic resection were the four independent factors differentiating group A from B patients. The 1‐, 3‐, 5‐, and 10‐year survival rates of the group A patients were 100%, 100%, 100%, and 40%, whereas those of the group B patients were 46.0%, 9.5%, 0%, and 0%, respectively. Absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatectomy could independently predict PCC patients with long‐term overall survival after hepatectomy.
Title: Clinicopathological Factors Predicting Long‐term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma
Description:
AbstractPeripheral cholangiocarcinoma (PCC) is clinically challenging because patients typically do not present until the disease is relatively advanced.
Three‐year to 5‐year survival rates even with resection thus remain dismal.
This study aimed to determine the clinicopathological factors for predicting overall survival longer than 5 years in PCC patients treated with hepatectomy.
From 1977 to 1997, the clinicopatholgical features of 11 PCC patients who underwent hepatectomy with long‐term overall survival (group A) were reviewed.
Comparison was made with the clinical features and factors influencing the outcome of 70 PCC patients who survived less than 5 years after hepatectomy (group B).
Of 81 PCC patients undergoing hepatectomy, 11 (13.
6%) were 5‐year survivors.
The 81 PCC patients comprised 32 men and 49 women, with a mean age of 56.
0 years (range: 34–83 years).
Univariate analysis showed that female gender, absence of physical findings, a higher percentage of presence of mucobilia, early staged tumor, intraductal papillary tumor growth, and curative hepatic resection were more frequent in group A patients than group B patients.
However, multivariate logistic regression analysis showed that absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatic resection were the four independent factors differentiating group A from B patients.
The 1‐, 3‐, 5‐, and 10‐year survival rates of the group A patients were 100%, 100%, 100%, and 40%, whereas those of the group B patients were 46.
0%, 9.
5%, 0%, and 0%, respectively.
Absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatectomy could independently predict PCC patients with long‐term overall survival after hepatectomy.
Related Results
Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker
Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker
Abstract
Background
Distal cholangiocarcinoma is an aggressive malignancy with a dismal prognosis. Diagnostic and prognostic biomarkers for distal c...
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma Aims: The c‐erbB‐2 and c‐Met proto‐oncogenes are important for ...
Caudate lobe-based minimally invasive anatomic hepatectomy: a retrospective study
Caudate lobe-based minimally invasive anatomic hepatectomy: a retrospective study
Abstract
Background: Anatomic hepatectomy has become a crucial surgical procedure in the liver section. The function and role of the caudate lobe in anatomic hepatectomy re...
Risk Factors of Post-Partial Hepatectomy Acute Myocardial Infarction : A Retrospective Nationwide Inpatient Sample Database Study
Risk Factors of Post-Partial Hepatectomy Acute Myocardial Infarction : A Retrospective Nationwide Inpatient Sample Database Study
Abstract
Background
The aftermath of partial hepatectomy often results in a severe condition known as acute myocardial infarction (AMI), which may lead to death and frequen...
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
Regional versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a randomized controlled trial protocol
ABSTRACTIntroductionThe mainstay treatment for intrahepatic cholangiocarcinoma is surgical resection, the impact of lymph node dissection and the scope of lymph node dissection for...
Abstract 1400: C1GALT1 regulates malignant phenotypes of cholangiocarcinoma cells
Abstract 1400: C1GALT1 regulates malignant phenotypes of cholangiocarcinoma cells
Abstract
Identifying molecular targets for cholangiocarcinoma is an urgent need to overcome the treatment failure and death from cancer cell invasion and metastasis....
The diagnosis and treatment of cholangiocarcinoma
The diagnosis and treatment of cholangiocarcinoma
Background: Cholangiocarcinoma (CCA) is the second most common primary hepatic tumor. In recent years, its prognosis has improved because of wide resections and the establishment o...
Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
Introduction: Intrahepatic cholangiocarcinoma (ICC) has devastating outcomes owing to its advanced stage at diagnosis and high recurrence after hepatectomy. There is no preferred t...


